Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of DXP-106 as Monotherapy or in Combination With Standard of Care Chemotherapy in Patients With Advanced Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DX-2206 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Ewing's sarcoma; Head and neck cancer; Lung cancer; Pancreatic ductal carcinoma; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Singlomics Biopharmaceuticals

16 Apr 2026 New trial record
07 Apr 2026 According to Singlomics Biopharmaceuticals media release, the first patient has been dosed in the trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com